Taiho Oncology, Inc. announces results from TAS-102 global Phase III RECOURSE trial in refractory metastatic colorectal cancer
30 June 2014 | By Taiho Oncology
Taiho Oncology, Inc. announced detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug...